Thursday - May 1, 2025

LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

electroCore to Participate in the LD Micro Main Event XVI Conference

September 25, 2023 | Last Trade: US$7.46 0.10 1.36

ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.

LD Micro Main Event XVI:
Date: Tuesday, October 3, 2023
Time: 4:00 pm PDT
Event: Company presentation
Virtual viewers: Livestream

For more information regarding the conference and to register to watch the presentation live, please visit the conference page here.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page